These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23485467)

  • 1. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
    Kato Y; Natsume A; Kaneko MK
    Biochem Biophys Res Commun; 2013 Mar; 432(4):564-7. PubMed ID: 23485467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations.
    Kaneko MK; Tsujimoto Y; Hozumi Y; Goto K; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2013 Jun; 32(3):224-8. PubMed ID: 23750482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
    Kaneko MK; Tian W; Takano S; Suzuki H; Sawa Y; Hozumi Y; Goto K; Yamazaki K; Kitanaka C; Kato Y
    Biochem Biophys Res Commun; 2011 Mar; 406(4):608-13. PubMed ID: 21352804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
    Kato Kaneko M; Ogasawara S; Kato Y
    Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
    Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
    Kaneko MK; Morita S; Tsujimoto Y; Yanagiya R; Nasu K; Sasaki H; Hozumi Y; Goto K; Natsume A; Watanabe M; Kumabe T; Takano S; Kato Y
    Biochem Biophys Res Commun; 2013 Mar; 432(1):40-5. PubMed ID: 23376717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
    Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD
    Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
    Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y
    Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
    Takano S; Tian W; Matsuda M; Yamamoto T; Ishikawa E; Kaneko MK; Yamazaki K; Kato Y; Matsumura A
    Brain Tumor Pathol; 2011 Apr; 28(2):115-23. PubMed ID: 21344322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.
    Preusser M; Wöhrer A; Stary S; Höftberger R; Streubel B; Hainfellner JA
    J Neuropathol Exp Neurol; 2011 Aug; 70(8):715-23. PubMed ID: 21760534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
    Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG
    Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
    Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
    Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
    Bleeker FE; Lamba S; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Frattini M; Molinari F; Knowles M; Cerrato A; Rodolfo M; Scarpa A; Felicioni L; Buttitta F; Malatesta S; Marchetti A; Bardelli A
    Hum Mutat; 2009 Jan; 30(1):7-11. PubMed ID: 19117336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody specific for IDH1 R132H mutation.
    Capper D; Zentgraf H; Balss J; Hartmann C; von Deimling A
    Acta Neuropathol; 2009 Nov; 118(5):599-601. PubMed ID: 19798509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
    Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
    J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
    Pang B; Durso MB; Hamilton RL; Nikiforova MN
    Diagn Mol Pathol; 2013 Mar; 22(1):28-34. PubMed ID: 23370430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
    Sabit H; Nakada M; Furuta T; Watanabe T; Hayashi Y; Sato H; Kato Y; Hamada J
    Brain Tumor Pathol; 2014 Oct; 31(4):242-6. PubMed ID: 24384677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
    Kato Y; Kaneko MK
    Biochem Biophys Res Commun; 2013 Apr; 433(4):374-8. PubMed ID: 23524262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
    Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
    Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.